BRAF and melanoma: Thus, the purpose of this study was to assess clinical outcomes in patients with BRAF V600 mutation-positive advanced melanoma who received BRAF-targeted therapy in real-world settings in large state medical centers in Russia (outside of clinical trials) and to evaluate treatment choices in routine clinical practice.